JP2010526797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526797A5 JP2010526797A5 JP2010506953A JP2010506953A JP2010526797A5 JP 2010526797 A5 JP2010526797 A5 JP 2010526797A5 JP 2010506953 A JP2010506953 A JP 2010506953A JP 2010506953 A JP2010506953 A JP 2010506953A JP 2010526797 A5 JP2010526797 A5 JP 2010526797A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oligomer
- her3
- conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000178 monomer Substances 0.000 claims 18
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 15
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 230000003463 hyperproliferative effect Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 claims 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000005461 lubrication Methods 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 208000029255 peripheral nervous system cancer Diseases 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims 1
- 201000007321 sebaceous carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91739207P | 2007-05-11 | 2007-05-11 | |
| US2325008P | 2008-01-24 | 2008-01-24 | |
| PCT/EP2008/055779 WO2008138904A2 (en) | 2007-05-11 | 2008-05-09 | Rna antagonist compounds for the modulation of her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526797A JP2010526797A (ja) | 2010-08-05 |
| JP2010526797A5 true JP2010526797A5 (enExample) | 2011-06-23 |
Family
ID=40002684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506953A Pending JP2010526797A (ja) | 2007-05-11 | 2008-05-09 | Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8268793B2 (enExample) |
| EP (1) | EP2155877A2 (enExample) |
| JP (1) | JP2010526797A (enExample) |
| KR (1) | KR20100024410A (enExample) |
| CN (1) | CN101849007A (enExample) |
| AU (1) | AU2008250033A1 (enExample) |
| BR (1) | BRPI0811156A2 (enExample) |
| CA (1) | CA2686908A1 (enExample) |
| EA (1) | EA200971049A1 (enExample) |
| IL (1) | IL202038A0 (enExample) |
| MX (1) | MX2009012271A (enExample) |
| NZ (1) | NZ581201A (enExample) |
| TW (1) | TW200908987A (enExample) |
| WO (1) | WO2008138904A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| JP2010526797A (ja) | 2007-05-11 | 2010-08-05 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物 |
| JP2012508244A (ja) * | 2008-11-07 | 2012-04-05 | エンゾン ファーマシューティカルズ，インコーポレーテッド | ＥｒｂＢ−３（ＨＥＲ３）選択的併用療法 |
| AR076053A1 (es) * | 2009-04-14 | 2011-05-18 | Schering Corp | Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
| JP2014508782A (ja) | 2011-03-11 | 2014-04-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
| CN103429262A (zh) | 2011-03-15 | 2013-12-04 | 梅里麦克制药股份有限公司 | 克服对erbb途径抑制剂的抗性 |
| JP2015518712A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Ｍｅｃｐ２発現を調節するための組成物及び方法 |
| EA201492114A1 (ru) | 2012-05-16 | 2015-04-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии генов |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| CA2908096C (en) | 2013-03-27 | 2022-05-03 | Isarna Therapeutics Gmbh | Modified tgf-beta oligonucleotides |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10858650B2 (en) | 2014-10-30 | 2020-12-08 | The General Hospital Corporation | Methods for modulating ATRX-dependent gene repression |
| WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN116492365A (zh) * | 2022-01-19 | 2023-07-28 | 圣诺生物医药技术(广州)有限公司 | 抑制HER2和HER3的siRNA药物组合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| EP1042504A2 (en) | 1997-12-29 | 2000-10-11 | Genena Ltd. | A method for identifying and characterizing cells and tissues |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US6277640B1 (en) | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| US20050176024A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
| ES2280826T5 (es) * | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| DK2752488T3 (da) | 2002-11-18 | 2020-04-20 | Roche Innovation Ct Copenhagen As | Antisense-design |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| ES2576677T3 (es) * | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
| KR20060015505A (ko) | 2003-04-13 | 2006-02-17 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오타이드 전구약물 |
| KR101126560B1 (ko) | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | 약제 반응 예측 방법 |
| EP2439285B1 (en) * | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2007136989A2 (en) | 2006-05-05 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of dgat2 |
| CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
| EP2076257A4 (en) | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS |
| CN101554074B (zh) | 2006-10-30 | 2012-08-22 | 诺基亚公司 | 为用户设备提供运营商控制的移动性的方法、设备和系统 |
| CA2679757A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| US8575120B2 (en) | 2007-03-13 | 2013-11-05 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
| JP2010526797A (ja) | 2007-05-11 | 2010-08-05 | エンゾン ファーマシューティカルズ，インコーポレーテッド | Ｈｅｒ３のモジュレーションのためのｒｎａアンタゴニスト化合物 |
-
2008
- 2008-05-09 JP JP2010506953A patent/JP2010526797A/ja active Pending
- 2008-05-09 NZ NZ581201A patent/NZ581201A/en not_active IP Right Cessation
- 2008-05-09 EA EA200971049A patent/EA200971049A1/ru unknown
- 2008-05-09 KR KR1020097025807A patent/KR20100024410A/ko not_active Ceased
- 2008-05-09 CA CA002686908A patent/CA2686908A1/en not_active Abandoned
- 2008-05-09 US US12/118,271 patent/US8268793B2/en not_active Expired - Fee Related
- 2008-05-09 EP EP08759503A patent/EP2155877A2/en not_active Withdrawn
- 2008-05-09 WO PCT/EP2008/055779 patent/WO2008138904A2/en not_active Ceased
- 2008-05-09 AU AU2008250033A patent/AU2008250033A1/en not_active Abandoned
- 2008-05-09 CN CN200880024089A patent/CN101849007A/zh active Pending
- 2008-05-09 BR BRPI0811156A patent/BRPI0811156A2/pt not_active IP Right Cessation
- 2008-05-09 MX MX2009012271A patent/MX2009012271A/es active IP Right Grant
- 2008-05-09 TW TW097117351A patent/TW200908987A/zh unknown
-
2009
- 2009-11-10 IL IL202038A patent/IL202038A0/en unknown
-
2012
- 2012-06-22 US US13/531,307 patent/US20120295955A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526797A5 (enExample) | ||
| US20210340540A1 (en) | Chimeric double-stranded nucleic acid | |
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| CA2872304C (en) | Organic compositions to treat kras-related diseases | |
| US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
| JP2010524486A5 (enExample) | ||
| TW200908987A (en) | RNA antagonist compounds for the modulation of HER3 | |
| JP7553036B2 (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JP2011505798A5 (enExample) | ||
| WO2022061108A2 (en) | Therapeutic compositions for treating pain via multiple targets | |
| WO2016018193A1 (en) | Modified antimir-138 oligonucleotides | |
| JP2024519204A (ja) | 複数の標的を介して疼痛を処置するための治療組成物 | |
| CN116670276A (zh) | 用于通过多个靶标治疗疼痛的治疗组合物 | |
| US20250179497A1 (en) | Use of dinucleotide repeat rnas to treat cancer | |
| WO2020007702A1 (en) | Antisense oligonucleotides targeting bcl2l11 | |
| JP7498448B2 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JP7692829B2 (ja) | Ｍｕｒｆ１を標的とする核酸医薬 | |
| JP2021524450A (ja) | マイクロｒｎａ関連疾患の処置のための薬学的組成物 | |
| RU2788030C2 (ru) | Структуры мирнк с высокой активностью и сниженным воздействием вне мишени | |
| WO2020007700A1 (en) | Antisense oligonucleotides targeting spi1 |